Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to
become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with …

Hematopoietic stem cells (HSCs) maintain an organism's immune system for a lifetime, and
derangements in HSC proliferation and differentiation result in hematologic malignancies …

There has been a major revolution in the management of patients with myeloproliferative
neoplasms (MPN), and in particular those with myelofibrosis and extensive splenomegaly …

Myelofibrosis: Clinicopathologic Features, Prognosis, and Management Page 1 Clinical
Advances in Hematology & Oncology Volume 16, Issue 2 February 2018 121 Myelofibrosis …

Abstract JAK2V617F is the most common mutation in patients with BCR-ABL negative
myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem …

Myeloproliferative neoplasms (MPN) are a group of disorders defined by clonal proliferation
of mature myeloid cells with overlapping clinical features. The driver mutations of these …

Objective In an era of controversy in regard to 'hydroxyurea‐leukaemogenicity'and when
interferon‐alfa2 (IFN) is being revived in the treatment of Philadelphia‐negative …

Ruxolitinib was well tolerated and superior to best available therapy (including interferon
[IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and …

Introduction: The therapeutic landscape of the Philadelphia-negative myeloproliferative
neoplasms (MPNs) is markedly changing consequent to the development of JAK-inhibitors …

Patients with polycythemia vera (PV) experience shortened survival, increased risk of
thromboembolic and hemorrhagic events, and burdensome symptoms. For all patients with …